CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
免疫标志物与 HPV 16 感染及口咽鳞状细胞癌预后的相关性
英文原题：Correlation of immune makers with HPV 16 infections and the prognosis in oropharyngeal squamous cell carcinoma.
查看英文原题
Correlation of immune makers with HPV 16 infections and the prognosis in oropharyngeal squamous cell carcinoma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
研究概要
HPV + OPSCC 的预后显著更好，且 HPV + OPSCC 中 PD-L1 表达升高。
中文摘要
本研究旨在探讨免疫标志物与高危人乳头瘤病毒16型（HPV16）感染状态的关联，并评估程序性死亡配体1（PD-L1）对口咽鳞状细胞癌（OPSCC）患者的预后价值。
本回顾性研究收集了2011年1月至2015年12月的50例HPV阳性或阴性OPSCC病例。通过免疫荧光染色和实时定量PCR，分析CD8⁺TIL（肿瘤浸润淋巴细胞）、程序性死亡受体1（PD-1）和PD-L1表达与HPV16感染状态之间的相关性。
两组患者的基线资料无显著差异。与HPV阴性患者相比，HPV阳性OPSCC患者预后较好（5年总生存期［OS］66%比40%，P=0.003；5年疾病特异性生存期［DSS］73%比44%，P=0.001）。HPV阳性组免疫相关标志物表达显著较高（CD8⁺ TIL：P=0.039；PD-L1：P=0.005；PD-1：P=0.044）。CD8⁺ TIL和PD-L1阳性分别是OPSCC患者DSS（P<0.001）和OS（P<0.001）改善的独立因素。Kaplan–Meier生存分析显示，与HPV阳性/CD8⁺表达低、HPV阴性/CD8⁺表达高及HPV阴性/CD8⁺表达低的TIL患者相比，HPV阳性/CD8⁺表达高的TIL患者预后更好（DSS和OS比较的P值均<0.001；与HPV阴性/CD8⁺高表达组比较，DSS P=0.010，OS P=0.032）。此外，与HPV阳性/PD-L1阴性（DSS P<0.001，OS P=0.004）、HPV阴性/PD-L1阳性（DSS P=0.010，OS P=0.048）及HPV阴性/PD-L1阴性（DSS和OS的P值均<0.001）OPSCC患者相比，HPV阳性/PD-L1阳性患者预后显著更好。
HPV阳性OPSCC患者预后显著较好，且PD-L1表达升高。PD-L1阳性可能与HPV阳性OPSCC患者较好预后相关。
本研究为免疫检查点抑制剂应用于头颈部肿瘤提供了理论依据和基线数据。
展开英文摘要原文
This study aims to investigate the association of immune markers with high risk human papillomavirus 16 (HPV 16) infection status and to evaluate the prognostic value of programmed death ligand-1 (PD-L1) in patients with oropharyngeal squamous cell carcinoma (OPSCC).
This retrospective study collected 50 cases of HPV positive and HPV negative OPSCC from January 2011 to December 2015. The correlation of CD8 + tumor infiltrating lymphocytes (TILs), programmed death-1 (PD-1), and PD-L1 expression with HPV 16 infection status was analyzed via immunofluorescent staining and quantitative real-time PCR.
There was no significant difference in the baseline data between the two groups. Patients with HPV + OPSCC had better prognosis compared to HPV - patients (5-year overall survival [OS], 66% vs. 40%, P = 0.003; 5-year disease specific survival [DSS], 73% vs. 44%, P = 0.001). The expressions of immunity related makers were significantly higher in the HPV + group than the HPV - group (CD8 + TIL: P = 0.039; PD-L1: P = 0.005; PD-1: P = 0.044). Positive CD8 + TIL and PD-L1 were independent factors for better prognosis of OPSCC (DSS, P < 0.001; OS, P < 0.001, respectively). Kaplan-Meier survival analysis indicated that patients with TILs of high HPV + /CD8 + expression were more likely to have better prognosis than those with TILs of low HPV + /CD8 + expression (DSS, P < 0.001; OS, P < 0.001), TILs of high expression of HPV - /CD8 + (DSS, P = 0.010; OS, P = 0.032), and TILs of low expression of HPV - /CD8 + (DSS, P < 0.001; OS, P < 0.001). Furthermore, HPV + /PD-L1 + OPSCC patients had significant better prognosis compared to patients with HPV + /PD-L1 - (DSS, P < 0.001; OS, P = 0.004), HPV - /PD-L1 + (DSS, P = 0.010; OS, P = 0.048) and HPV - /PD-L1 - (DSS, P < 0.001; OS, P < 0.001).
HPV + OPSCC had a significantly better prognosis, and PD-L1 expression was elevated in HPV + OPSCC. PD-L1 positivity might be related to the better prognosis of HPV + OPSCC. CLINICAL RELEVANCE: This study provides a theoretical basis and baseline data for the application of immune checkpoint inhibitors in head and neck tumors.
论文信息
- 作者
- Zhu Y、Zhu X、Diao W、Liang Z、Gao Z、Chen X
- 第一作者单位
- Department of Otolaryngology-Head and Neck Surgery, Peking Union Medical College and Chinese Academy of Medical Sciences, Peking Union Medical College Hospital, No.1, Shuaifuyuan, Beijing, 100730, Wangfujing, China.China
- 通讯作者单位
- Department of Otolaryngology-Head and Neck Surgery, Peking Union Medical College and Chinese Academy of Medical Sciences, Peking Union Medical College Hospital, No.1, Shuaifuyuan, Beijing, 100730, Wangfujing, China. xingming.chen@hotmail.com.China
- 期刊
- Clinical oral investigations2023 Apr
- 原文标识
- PubMed 36884083 · DOI 10.1007/s00784-023-04926-2
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →